» Articles » PMID: 16079848

Licensing of Natural Killer Cells by Host Major Histocompatibility Complex Class I Molecules

Overview
Journal Nature
Specialty Science
Date 2005 Aug 5
PMID 16079848
Citations 624
Authors
Affiliations
Soon will be listed here.
Abstract

Self versus non-self discrimination is a central theme in biology from plants to vertebrates, and is particularly relevant for lymphocytes that express receptors capable of recognizing self-tissues and foreign invaders. Comprising the third largest lymphocyte population, natural killer (NK) cells recognize and kill cellular targets and produce pro-inflammatory cytokines. These potentially self-destructive effector functions can be controlled by inhibitory receptors for the polymorphic major histocompatibility complex (MHC) class I molecules that are ubiquitously expressed on target cells. However, inhibitory receptors are not uniformly expressed on NK cells, and are germline-encoded by a set of polymorphic genes that segregate independently from MHC genes. Therefore, how NK-cell self-tolerance arises in vivo is poorly understood. Here we demonstrate that NK cells acquire functional competence through 'licensing' by self-MHC molecules. Licensing involves a positive role for MHC-specific inhibitory receptors and requires the cytoplasmic inhibitory motif originally identified in effector responses. This process results in two types of self-tolerant NK cells--licensed or unlicensed--and may provide new insights for exploiting NK cells in immunotherapy. This self-tolerance mechanism may be more broadly applicable within the vertebrate immune system because related germline-encoded inhibitory receptors are widely expressed on other immune cells.

Citing Articles

IFN-α treatment may enable discontinuation of TKIs in NK cell-licensed patients with CML-CP.

Ureshino H, Kamachi K, Kidoguchi K, Kimura S EJHaem. 2024; 5(6):1278-1282.

PMID: 39691242 PMC: 11647684. DOI: 10.1002/jha2.1053.


Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.

Chen S, Zhu H, Jounaidi Y Signal Transduct Target Ther. 2024; 9(1):302.

PMID: 39511139 PMC: 11544004. DOI: 10.1038/s41392-024-02005-w.


Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy.

Li Y, Li Z, Tang Y, Zhuang X, Feng W, Boor P J Immunother Cancer. 2024; 12(10).

PMID: 39486805 PMC: 11529472. DOI: 10.1136/jitc-2024-009934.


Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments.

Kennedy P, Arvindam U, Phung S, Ettestad B, Feng X, Li Y Sci Adv. 2024; 10(44):eadn1849.

PMID: 39475618 PMC: 11524192. DOI: 10.1126/sciadv.adn1849.


The Role of Natural Killer Cells and Their Metabolism in HIV-1 Infection.

Naidoo K, Altfeld M Viruses. 2024; 16(10).

PMID: 39459918 PMC: 11512232. DOI: 10.3390/v16101584.